Regulation of megalin expression in cultured proximal tubule cells by angiotensin II type 1A receptor- and insulin-mediated signaling cross talk. 2009

Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Impairment of proximal tubular endocytosis of glomerular-filtered proteins including albumin results in the development of proteinuria/albuminuria in patients with chronic kidney disease. However, the mechanisms regulating the proximal tubular function are largely unknown. This study aimed to investigate the role of angiotensin II type 1A receptor (AT(1A)R)- and insulin-mediated signaling pathways in regulating the expression of megalin, a multiligand endocytic receptor in proximal tubule cells (PTCs). Opossum kidney PTC-derived OK cells that stably express rat AT(1A)R but are deficient in endogenous angiotensin II receptors (AT(1A)R-OK cells) were used for this study. Treatment of the cells with angiotensin II suppressed mRNA and protein expression of megalin at 3- and 24-h incubation time points, respectively. Cellular uptake and degradation of albumin and receptor-associated protein, megalin's endocytic ligands were suppressed 24 h after angiotensin II treatment. The AT(1A)R-mediated decrease in megalin expression was partially prevented by ERK inhibitors. Insulin competed with the AT(1A)R-mediated ERK activation and decrease in megalin expression. Inhibitors of phosphatidylinositol 3-kinase (PI3K), a major component of insulin signaling, also suppressed megalin expression, and activation of the insulin receptor substrate (IRS)/PI3K system was prevented by angiotensin II. Collectively the AT(1A)R-mediated ERK signaling is involved in suppressing megalin expression in the OK cell line, and insulin competes with this pathway. Conversely, the insulin-IRS/PI3K signaling, with which angiotensin II competes, tends to stimulate megalin expression. In conclusion, there is AT(1A)R- and insulin-mediated competitive signaling cross talk to regulate megalin expression in cultured PTCs.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007687 Kidney Tubules, Proximal The renal tubule portion that extends from the BOWMAN CAPSULE in the KIDNEY CORTEX into the KIDNEY MEDULLA. The proximal tubule consists of a convoluted proximal segment in the cortex, and a distal straight segment descending into the medulla where it forms the U-shaped LOOP OF HENLE. Proximal Kidney Tubule,Proximal Renal Tubule,Kidney Tubule, Proximal,Proximal Kidney Tubules,Proximal Renal Tubules,Renal Tubule, Proximal,Renal Tubules, Proximal,Tubule, Proximal Kidney,Tubule, Proximal Renal,Tubules, Proximal Kidney,Tubules, Proximal Renal
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004705 Endocytosis Cellular uptake of extracellular materials within membrane-limited vacuoles or microvesicles. ENDOSOMES play a central role in endocytosis. Endocytoses
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal

Related Publications

Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
February 2018, Journal of the American Society of Hypertension : JASH,
Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
July 2014, American journal of physiology. Renal physiology,
Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
October 2000, Kidney international,
Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
September 1997, Seminars in nephrology,
Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
January 1991, Renal physiology and biochemistry,
Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
March 1999, International journal of molecular medicine,
Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
July 1997, Kidney international,
Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
June 2007, Biochemical and biophysical research communications,
Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
March 1998, Renal failure,
Michihiro Hosojima, and Hiroyoshi Sato, and Keiko Yamamoto, and Ryohei Kaseda, and Taeko Soma, and Asako Kobayashi, and Akiyo Suzuki, and Hideyuki Kabasawa, and Aya Takeyama, and Kenji Ikuyama, and Noriaki Iino, and Akira Nishiyama, and Thomas J Thekkumkara, and Tetsuro Takeda, and Yoshiki Suzuki, and Fumitake Gejyo, and Akihiko Saito
January 1988, Progress in clinical and biological research,
Copied contents to your clipboard!